Ignalis-M 100/1000 Tablet ER is a combination oral antidiabetic medication containing Sitagliptin 100 mg and Metformin 1000 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus in adults, particularly for patients who have inadequate glycemic control with diet and exercise alone or those already treated with either component. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the levels of incretin hormones, thereby increasing insulin secretion in response to meals and decreasing glucagon secretion, which helps regulate blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining more stable plasma drug concentrations. Ignalis-M 100/1000 should be used as an adjunct to diet and exercise and is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic control is recommended during therapy to optimize efficacy and minimize potential risks.